Steven Hoerter Buys 62,000 Shares of C4 Therapeutics
C4 Therapeutics insider Steven Hoerter acquired 62,000 shares on June 24, 2026.
Key Points
- Steven Hoerter acquired 62,000 shares of C4 Therapeutics on June 24, 2026, with shares trading at $4.40 on Saturday.
- C4 Therapeutics, with a market cap of $471 million, has a 52-week range between $1.40 and $4.60 and a beta of 2.93.
- Analysts maintain a 'strong buy' rating with a mean price target of $13.33, highlighting positive sentiment.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 24, 2026, Steven Hoerter, an insider at C4 Therapeutics, Inc. (NasdaqGS: CCCC), purchased 62,000 shares of the company. The transaction was not part of a pre-planned trading program. Shares of C4 Therapeutics were trading at $4.40 on the previous Saturday.
Insider Buying and Selling at C4 Therapeutics, Inc.
A notable insider buying activity took place on June 24, 2026, at C4 Therapeutics. Steven Hoerter, along with other insiders including Laura Bessen, Stephen Fawell, Owen Hughes, and Donna Roy Grogan, each acquired 62,000 shares of the company. Kenneth Carl Anderson also bought 1,070 shares earlier in the month on June 1, 2026, at an average price of $2.11 per share.
Other Institutional Activity in C4 Therapeutics
Morgan Stanley increased its holdings in C4 Therapeutics by 90,738 shares, bringing its total to 9,072,400 shares valued at approximately $23.86 million. RA Capital Management, L.P. maintained its position with 8,000,000 shares worth about $21.04 million. Bain Capital Life Sciences Investors, LLC also held steady with 7,171,910 shares valued at $18.86 million. Lynx1 Capital Management LP trimmed its stake by 99,231 shares, leaving it with 6,998,902 shares worth approximately $18.41 million. Vanguard Capital Management LLC opened a new position with 3,861,852 shares valued at around $10.16 million.
C4 Therapeutics, Inc. Stock Up 10.6%
C4 Therapeutics, Inc. has a market capitalization of about $471 million. The stock has experienced a 52-week low of $1.40 and a high of $4.60. Its 50-day moving average is $3.51, while the 200-day moving average stands at $2.70. The company has a high beta of 2.93, indicating higher volatility compared to the market. C4 Therapeutics maintains a strong liquidity position with a current ratio of 9.01 and a quick ratio of 8.76, alongside a debt-to-equity ratio of 24.95.
$CCCC stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
C4 Therapeutics reported revenue of $34.86 million, though it experienced a decline in revenue growth by 15%. The company has a negative net margin of approximately -298% and a return on equity of -48.35%. The next earnings release is scheduled for August 6, 2026.
Analysts Set New Price Targets
Analysts remain optimistic about C4 Therapeutics. On June 1, 2026, Evercore ISI Group maintained its 'buy' rating with a price target of $12. Barclays, on February 27, 2026, also maintained a 'buy' rating with a target of $7. Brookline Capital, earlier on February 23, 2026, set a target price of $30, reaffirming its 'buy' stance. The consensus among six analysts is a 'strong buy' rating with an average price target of $13.33.
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. The company specializes in developing therapies that degrade disease-causing proteins. Its lead candidate, Cemsidomide, targets proteins involved in multiple myeloma. C4 Therapeutics is also working on treatments for non-small cell lung cancer and other conditions related to inflammation and neurodegeneration. The company collaborates with major firms like Roche and Merck for developing innovative cancer treatments.
Bottom Line
Insider buying activity at C4 Therapeutics, including by Steven Hoerter, suggests confidence in the company's future. The stock's recent trading range and analyst ratings indicate a positive outlook. Investors keep a close watch on such insider transactions for potential insights into the company's prospects.
Get C4 Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CCCC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.